Pegloticase Injection Uses, Dosage, Side Effects and Interactions
Krystexxa
Krystexxa is a brand of pegloticase injection that comes as an injection.
Pegloticase Injection (Krystexxa) is an intravenous enzyme medicine for adults with chronic gout that has not responded to conventional treatment.
Quick links
Ask Anything About Pegloticase InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Pegloticase Injection in Short
- Drug class Uric Acid-specific Enzyme How the FDA classifies it
What it treatsKrystexxa (pegloticase) treats chronic gout in adults who are refractory to conventional therapy. That means uric acid levels did not normalize, and symptoms stayed uncontrolled, despite the maximum appropriate dose of xanthine oxidase inhibitors (such as allopurinol).
- How you get it Prescription only
- Comes asInjection (into a vein)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Supplements and herbs1 interacts 1 moderate, none major
The Pharmacist’s Take
Pegloticase (Krystexxa) is an enzyme given by IV (into a vein) for adults with chronic gout that allopurinol-type medicines have not controlled. It turns uric acid into allantoin, which the kidneys clear, and it is a specialist, last-resort option, on the market since about 2010 with no generic. Gout flares often get worse early on as stored uric acid dissolves, so colchicine or an anti-inflammatory is started beforehand, and nausea, joint pain and tiredness are common. Its boxed warning covers anaphylaxis (a severe allergic reaction) and infusion reactions with any infusion. It also covers red blood cell breakdown and poor blood oxygen delivery in people with G6PD deficiency, an inherited condition checked for first.
Key Takeaways From the HelloPharmacist Team
- Expect an IV infusion in a clinic every two weeks, taking at least two hours, with antihistamines and steroids beforehand and monitoring afterward.
- Get emergency help for wheezing, trouble breathing, lip or tongue swelling, hives or feeling faint, even after you have left the clinic.
- Stop oral gout medicines like allopurinol before starting, because they can hide the rising uric acid that signals a higher reaction risk.
- Take weekly methotrexate by mouth with folic acid, started at least four weeks ahead, unless your prescriber says it is not right for you.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Pegloticase Injection.
Krystexxa can cause severe, life-threatening allergic reactions (anaphylaxis) and infusion reactions. These usually appear within 2 hours of an infusion, but delayed reactions can occur. That is why it is given only in a healthcare setting with premedication and monitoring afterward.
Your uric acid is checked before each infusion. Treatment stops if it rises above 6 mg/dL, because this raises reaction risk.
It can also cause red blood cell breakdown and methemoglobinemia in people with G6PD deficiency. It must not be used in those people. Screening is done first if you are at risk.
Patient Information Guide for Pegloticase Injection
What It’s Used For
Pegloticase Injection is used for one condition.
- Krystexxa (intravenous) treats chronic gout in adults who are refractory to conventional therapy.
- Krystexxa is not recommended for asymptomatic hyperuricemia.
How It Works
Pegloticase is a PEGylated enzyme (a recombinant uricase). It converts uric acid into allantoin, an inert, water-soluble substance. The kidneys then clear it. This lowers uric acid in the blood.
Drug Class
Drug Class
- Uric Acid-specific Enzyme
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Uric Acid-specific Enzyme
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Pegloticase Injection in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Pegloticase Injection in the FDA’s index.
From our Patient Information GuidePegloticase is a PEGylated enzyme (a recombinant uricase). It converts uric acid into allantoin, an inert, water-soluble substance. The kidneys then clear it. This lowers uric acid in the blood. Read How Pegloticase Injection Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Urate Oxidase
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Other antigout preparations
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Krystexxa is an IV infusion given in a healthcare setting, usually every two weeks. Each infusion runs at least 120 minutes.
- Usually given with weekly oral methotrexate and folic or folinic acid, started at least 4 weeks earlier.
- Can be used alone if methotrexate is not appropriate.
- Premedication with antihistamines and corticosteroids is given before infusions.
- Oral urate-lowering medicines are stopped beforehand.
- The best treatment length has not been established.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Long-lasting gout that has not responded to other treatments
Adults taking methotrexate with it Usual dose 8 mg by IV infusion every two weeks
- Krystexxa 8 mg given as an intravenous infusion every two weeks, co-administered with weekly oral methotrexate 15 mg and folic acid or folinic acid supplementation
- Start methotrexate and folic acid or folinic acid at least 4 weeks prior to initiating Krystexxa and continue throughout treatment
IV means given into a vein (intravenous).
Adults who cannot take methotrexate Usual dose 8 mg by IV infusion every two weeks
- Krystexxa 8 mg given as an intravenous infusion every two weeks
IV means given into a vein (intravenous).
Good to Know for Every Dose
Ready-to-Use vial infused over a period of no less than 120 minutes; To-be-Diluted vial infused over 120 minutes
Side Effects
Common side effects seen in studies include:
Common side effects
- Gout flares
- Infusion reactions
- Nausea
- Joint pain (arthralgia)
- Fatigue
- Bruising (contusion or ecchymosis)
- Constipation
- Vomiting
When to get medical help
- Get emergency help right away for wheezing, trouble breathing, swelling of the lips or tongue, hives, a drop in blood pressure, or feeling faint after an infusion. These can be signs of anaphylaxis (a severe allergic reaction). They can happen after you leave the healthcare setting.
- Tell your care team right away about chest discomfort, chest pain, itching, rash, or shortness of breath during or after an infusion.
- Tell your doctor about symptoms of hemolysis (red blood cells breaking down) or methemoglobinemia (low oxygen delivery by the blood), especially if you have G6PD deficiency.
- Report worsening heart failure symptoms after an infusion if you have heart failure.
- Call your doctor if gout flares seem severe. Treatment usually continues during a flare.
Seek care right away for signs of anaphylaxis, such as wheezing, swelling of the face or tongue, hives, or fainting.
Warnings and Precautions
- Anaphylaxis and infusion reactions: can occur with any infusion, mostly within 2 hours. Risk is higher when uric acid rises above 6 mg/dL.
- G6PD deficiency: can cause life-threatening hemolysis and methemoglobinemia. Do not use if you have it.
- Gout flares: common early on. Prevention with an NSAID or colchicine is recommended for at least 6 months.
- Heart failure: may worsen. Close monitoring after infusion is advised.
- Re-treatment: after a break longer than 4 weeks, reaction risk may be higher.
Interactions
A few things matter with Krystexxa.
- Methotrexate may raise Krystexxa levels, and it lowers antibody formation.
- Oral urate-lowering drugs can hide a rise in uric acid, so they are stopped before starting.
- Other PEGylated products: antibodies to Krystexxa may bind PEG, with unknown effects.
Interactions Listed in the FDA-Approved Label
From the Pegloticase Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
What happensCo-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone.
-
PEGylated productsWhat happensBecause anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products; the impact of anti-PEG antibodies on responses to other PEG-containing therapeutics is unknown.
-
Oral urate-lowering agentsWhat happensThe label recommends patients stop oral urate-lowering medications before starting KRYSTEXXA and not start them while on KRYSTEXXA therapy.What to doDiscontinue oral urate-lowering agents before starting KRYSTEXXA and do not institute them during therapy.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly. Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone. 7.2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients' responses to other PEG-containing therapeutics is unknown.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use with G6PD deficiency or a past serious allergic reaction to Krystexxa.
- Tell your doctor if you have heart failure.
- Pregnancy: no adequate studies in people.
- Breastfeeding: not recommended unless the clear benefit outweighs the unknown risk.
- Children under 18: safety and effectiveness are not established.
- Older adults and people with kidney impairment: no dose adjustment needed.
Overdose
No overdoses have been reported. The largest single IV dose given was 12 mg. If an overdose is suspected, you would be monitored and given supportive care, since there is no specific antidote.
How Your Body Processes It
Blood levels of pegloticase rose in proportion to the dose. Age, sex, weight, and creatinine clearance did not affect it. Body surface area and anti-pegloticase antibodies did. People with higher antibody levels cleared the drug faster and had less benefit. Taking methotrexate with it lowered antibody formation and raised drug levels.
Storage
Stored in the carton and maintained at all times under refrigeration between 2°C to 8°C (36°F to 46°F). Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Pegloticase Injection
From the licensed clinical database we use, rolled up per supplement, most serious first.1 supplement and herbal product has documented interactions with Pegloticase Injection in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Moderate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Pegloticase Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Pegloticase Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Krystexxa used for?
How is Krystexxa given, and how long does it take?
Why do I need methotrexate and to stop my other gout pills?
Will my gout get worse at first?
What side effects should I call about?
Can I use Krystexxa if I'm pregnant or breastfeeding?
Is pegloticase injection available over the counter?
When was pegloticase injection first available?
What is the brand name of pegloticase injection?
What is the generic name of Krystexxa?
What drug class is pegloticase injection?
What strengths does pegloticase injection come in?
Where can I read the pegloticase injection prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Pegloticase Injection
Skip the scrolling. Ask in your own words and get an answer from Pegloticase Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Pegloticase Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Pegloticase Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Pegloticase Injection Forms and Strengths (How It Comes)
Pegloticase Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Pegloticase Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Krystexxa is used for chronic gout in adults refractory to conventional therapy.
- Krystexxa is not recommended for asymptomatic hyperuricemia.
- Krystexxa is given only as an intravenous infusion, never as an IV push or bolus.
- Krystexxa is infused over at least 120 minutes in a healthcare setting.
- Krystexxa is supplied as a Ready-to-Use vial or a To-be-Diluted vial, prepared by healthcare providers.
- Krystexxa is usually given with weekly oral methotrexate plus folic or folinic acid, unless methotrexate is not appropriate.
Pegloticase Injection on the U.S. Market: Products, Makers and Brands
How Pegloticase Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Pegloticase Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2010. The one brand name in the directory today is Krystexxa; the rest are generics.
How Widely Pegloticase Injection Is Used (Medicaid Data)
How many Pegloticase Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Pegloticase Injection prescribed? Of the 1,682 medications we measure, Pegloticase Injection ranks #1,165 by Medicaid prescriptions — more than 31% of them.
Utilization by Pegloticase Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
1 ML pegloticase 8 MG/ML Injection Most dispensed
1 of 1 listed NDCs had Medicaid claims. RxNorm 1011653
50 ML pegloticase 0.16 MG/ML Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 2723378
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 2 listed Pegloticase Injection NDCs had Medicaid claims.
Compare Pegloticase Injection Products
A representative set of FDA-listed product records for Pegloticase Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 8 mg/50 mL | Intravenous | Horizon Therapeutics USA, Inc. | BLA | View NDC → |
| 8 mg/mL | Intravenous | Horizon Therapeutics USA, Inc. | BLA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Pegloticase Injection NDCs →
Pegloticase Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Pegloticase Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Pegloticase Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Pegloticase Injection FDA Approval History
How Pegloticase Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Pegloticase Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Pegloticase recalls since July 2021.
✅No Pegloticase recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Pegloticase Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 2
- Forms in current FDA listings
- 1 of 1
RxCUI 1011650 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1811408Its 2 strengths (SCD)-
1 mL pegloticase 8 mg/mL
RxCUI 1011653 -
50 mL pegloticase 0.16 mg/mL
RxCUI 2723378
-
1 mL pegloticase 8 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Pegloticase Injection Supply and Shortage Status
Whether Pegloticase Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Pegloticase Injection Brand Names
Pegloticase Injection has one brand name on record: Krystexxa. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Pegloticase Injection: Manufacturers and Labelers
One company lists Pegloticase Injection products with the FDA. By number of product records, the largest are Horizon Therapeutics USA, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Pegloticase Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Horizon Therapeutics USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →